Related Experiment Video

Updated: Jan 20, 2026

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers
03:37

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Published on: March 1, 2024

1.3K

Predictive biomarkers for EGFR therapy

Akira Sakurada1, Ming-Sound Tsao

  • 1Princess Margaret Hospital and Ontario Cancer Institute, University Health Network, 610 University Avenue, Toronto, ON M5G2M9, Canada.

Idrugs : the Investigational Drugs Journal
|January 8, 2009
PubMed

Insights

Erlotinib offers new lung cancer treatment options. Identifying predictive biomarkers like EGFR mutations is crucial for patient selection, though results remain controversial.

Area of Science:

  • Oncology
  • Pharmacogenomics
  • Biomarker Discovery

Background:

  • The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) BR.21 study evaluated erlotinib for advanced non-small cell lung cancer (NSCLC).
  • Targeted therapies like epidermal growth factor receptor (EGFR) inhibitors show promise, but only a subset of patients benefit.
  • Identifying predictive biomarkers is essential for optimizing treatment selection and improving outcomes in NSCLC.

Purpose of the Study:

  • To review the evidence and controversies surrounding biomarkers predictive of erlotinib benefit in advanced NSCLC.
  • To discuss the role of EGFR tyrosine kinase domain mutations, EGFR gene copy number, and KRAS mutations as predictive markers.

Main Methods:

  • Analysis of data from the NCIC CTG BR.21 phase III trial.
  • Review of existing literature on biomarkers for EGFR-targeted therapies in NSCLC.
  • Discussion of conflicting results and their potential explanations.

Main Results:

  • Erlotinib demonstrated efficacy in advanced NSCLC patients who failed prior chemotherapy.
  • Biomarkers such as EGFR mutations, gene copy number, and KRAS mutations have been investigated for predicting response.
  • Current data on these biomarkers' predictive value remains controversial and requires further clarification.

Conclusions:

  • Predictive biomarkers are critical for personalizing erlotinib treatment in NSCLC.
  • Further research is needed to resolve controversies and establish reliable biomarkers for EGFR inhibitor therapy.
  • Optimizing patient selection through validated biomarkers can enhance treatment efficacy and reduce unnecessary toxicity.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.6K
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.4K

Related Concept Videos

Generating the Transcriptional Regulation View of Transcriptomic Features for Prediction Task and Dark Biomarker Detection on Small Datasets03:37

Generating the Transcriptional Regulation View of Transcriptomic Features for Prediction Task and Dark Biomarker Detection on Small Datasets

Here, we introduce a protocol for converting transcriptomic data into a mqTrans view, enabling the identification of dark biomarkers. While not differentially expressed in conventional transcriptomic analyses, these biomarkers exhibit differential expression in the mqTrans view. The approach serves as a complementary technique to traditional methods, unveiling previously overlooked...
1.3K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

This protocol describes a standardized evaluation of drug sensitivities to targeted signaling inhibitors in NSCLC patient-derived organoid...
4.6K
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

The genetically tractable nematode Caenorhabditis elegans can be used as a simple and inexpensive model for drug discovery. Described here is a protocol to identify anticancer therapeutics that inhibit the downstream signaling of RAS and EGFR...
3.4K
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

The objective of this protocol is to use molecular dynamics simulations to examine the dynamic structural changes that occur due to activating mutations of the EGFR kinase...
9.2K
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Intra-arterial therapies are the standard of care for patients with hepatocellular carcinoma who cannot undergo surgical resection. A method for predicting response to these therapies is proposed. The technique uses pre-procedural clinical, demographic, and imaging information to train machine learning models capable of predicting response prior to...
8.6K
Predicting Molecular Geometry02:27

Predicting Molecular Geometry

VSEPR Theory for Determination of Electron Pair Geometries
45.4K